Orchard Therapeutics plc

2023 Q4 Form 10-Q Financial Statement

#000095017023062428 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $125.4M
YoY Change -14.43%
Cash & Equivalents $23.47M
Short-Term Investments $101.9M
Other Short-Term Assets $4.900M
YoY Change -56.48%
Inventory $6.638M
Prepaid Expenses
Receivables $6.187M
Other Receivables $10.80M
Total Short-Term Assets $153.9M
YoY Change -14.13%
LONG-TERM ASSETS
Property, Plant & Equipment $7.131M
YoY Change -8.62%
Goodwill
YoY Change
Intangibles $3.321M
YoY Change -4.76%
Long-Term Investments
YoY Change
Other Assets $10.30M
YoY Change -12.65%
Total Long-Term Assets $48.34M
YoY Change -11.78%
TOTAL ASSETS
Total Short-Term Assets $153.9M
Total Long-Term Assets $48.34M
Total Assets $202.3M
YoY Change -13.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.661M
YoY Change -43.83%
Accrued Expenses $35.50M
YoY Change 2.85%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $9.429M
YoY Change 20.01%
Total Short-Term Liabilities $49.38M
YoY Change -1.77%
LONG-TERM LIABILITIES
Long-Term Debt $16.16M
YoY Change -36.03%
Other Long-Term Liabilities $8.377M
YoY Change 26.29%
Total Long-Term Liabilities $24.54M
YoY Change 269.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $49.38M
Total Long-Term Liabilities $24.54M
Total Liabilities $122.0M
YoY Change 10.57%
SHAREHOLDERS EQUITY
Retained Earnings -$965.9M
YoY Change 8.17%
Common Stock $29.46M
YoY Change 79.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $80.26M
YoY Change
Total Liabilities & Shareholders Equity $202.3M
YoY Change -13.58%

Cashflow Statement

Concept 2023 Q4 2023 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001748907
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Line Of Credit Facility Initiation Date1
LineOfCreditFacilityInitiationDate1
2019-05-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38722
dei Entity Registrant Name
EntityRegistrantName
ORCHARD THERAPEUTICS PLC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
X0
dei Entity Address Address Line1
EntityAddressAddressLine1
245 Hammersmith Road
dei Entity Address City Or Town
EntityAddressCityOrTown
London
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
W6 8PW
dei Entity Address Country
EntityAddressCountry
GB
dei City Area Code
CityAreaCode
44
dei Local Phone Number
LocalPhoneNumber
(0) 203 808-8286
dei Security12b Title
Security12bTitle
American Depositary Shares, each representing tenordinary shares, nominal value £0.10 per share
dei Trading Symbol
TradingSymbol
ORTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
227610439
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23469000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68424000
CY2023Q3 us-gaap Marketable Securities
MarketableSecurities
101944000
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
75326000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6187000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8467000
CY2023Q3 us-gaap Inventory Net
InventoryNet
6638000
CY2022Q4 us-gaap Inventory Net
InventoryNet
3400000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7451000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6586000
CY2023Q3 ortx Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
8234000
CY2022Q4 ortx Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
5942000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
153923000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
168145000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20001000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22774000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7131000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8138000
CY2023Q3 ortx Research And Development Tax Credit Receivable Noncurrent
ResearchAndDevelopmentTaxCreditReceivableNoncurrent
3372000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4215000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4215000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1950000
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3321000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3560000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10303000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12075000
CY2023Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
48343000
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
50762000
CY2023Q3 us-gaap Assets
Assets
202266000
CY2022Q4 us-gaap Assets
Assets
218907000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3661000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9318000
CY2023Q3 ortx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
29995000
CY2022Q4 ortx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
34437000
CY2023Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
742000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
959000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5548000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6424000
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
9429000
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
9429000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
49375000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
60567000
CY2023Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
16162000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
22991000
CY2023Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
10345000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
10315000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16681000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19246000
CY2023Q3 ortx Pipe Warrant Liabilities
PipeWarrantLiabilities
21068000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8377000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7524000
CY2023Q3 us-gaap Liabilities
Liabilities
122008000
CY2022Q4 us-gaap Liabilities
Liabilities
120643000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.10
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.10
CY2023Q3 ortx Common Stock Shares Authorized Nominal Amount
CommonStockSharesAuthorizedNominalAmount
33556809
CY2022Q4 ortx Common Stock Shares Authorized Nominal Amount
CommonStockSharesAuthorizedNominalAmount
13023851.5
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
227273209
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
227273209
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
126947225
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
126947225
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
29463000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
16419000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
994108000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
956711000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
22609000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
26018000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-965922000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-900884000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
80258000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
98264000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
202266000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
218907000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6302000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5777000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14853000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15669000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1745000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1645000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4301000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4338000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14553000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18103000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47241000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
68302000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11609000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11496000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
33736000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
38525000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
27907000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
31244000
us-gaap Costs And Expenses
CostsAndExpenses
85278000
us-gaap Costs And Expenses
CostsAndExpenses
111165000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21605000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-25467000
us-gaap Operating Income Loss
OperatingIncomeLoss
-70425000
us-gaap Operating Income Loss
OperatingIncomeLoss
-95496000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1505000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
404000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3925000
us-gaap Investment Income Interest
InvestmentIncomeInterest
686000
CY2023Q3 us-gaap Interest Expense
InterestExpense
932000
CY2022Q3 us-gaap Interest Expense
InterestExpense
799000
us-gaap Interest Expense
InterestExpense
2864000
us-gaap Interest Expense
InterestExpense
2146000
CY2023Q3 ortx Changes In Fair Value Of Pipe Warrant And Pipe Unit Liabilities
ChangesInFairValueOfPipeWarrantAndPipeUnitLiabilities
-8801000
ortx Changes In Fair Value Of Pipe Warrant And Pipe Unit Liabilities
ChangesInFairValueOfPipeWarrantAndPipeUnitLiabilities
3256000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4510000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-22787000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2059000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-47066000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12738000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-23182000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6376000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-48526000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34343000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-48649000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-64049000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-144022000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
976000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1084000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
989000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1245000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-35319000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-47565000
us-gaap Net Income Loss
NetIncomeLoss
-65038000
us-gaap Net Income Loss
NetIncomeLoss
-142777000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.12
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
228388561000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
228388561000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
128132092000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
128132092000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
186811772000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
186811772000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
127895426000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
127895426000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3978000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
21459000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3523000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
44504000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
79000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
84000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
114000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-177000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4057000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
21543000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3409000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
44327000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31262000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26022000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-68447000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-98450000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
209950000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4660000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-1000
CY2022Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-3000
CY2022Q1 ortx Stock Issued During Period Value As Part Of Consulting Agreement
StockIssuedDuringPeriodValueAsPartOfConsultingAgreement
1000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5595000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-260000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-44296000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
175646000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3956000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
136000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
17450000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-50916000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
146272000
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3468000
CY2022Q3 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-15000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
21459000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
84000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-47565000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
123703000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
98264000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3512000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
41000
CY2023Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-166000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
889000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
23073000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5731000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
74000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-17412000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
101655000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2578000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
169000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
953000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18761000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1770000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-39000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-12307000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
109047000
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2468000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
18000
CY2023Q3 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-13000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3978000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
79000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-35319000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
80258000
us-gaap Profit Loss
ProfitLoss
-65038000
us-gaap Profit Loss
ProfitLoss
-142777000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2020000
us-gaap Share Based Compensation
ShareBasedCompensation
8558000
us-gaap Share Based Compensation
ShareBasedCompensation
12084000
ortx Non Cash Interest Expense
NonCashInterestExpense
266000
ortx Non Cash Interest Expense
NonCashInterestExpense
279000
ortx Amortization Of Provision On Loss Contract
AmortizationOfProvisionOnLossContract
-2900000
ortx Amortization Of Provision On Loss Contract
AmortizationOfProvisionOnLossContract
-276000
ortx Accretion Amortization Of Discount Premium On Marketable Securities
AccretionAmortizationOfDiscountPremiumOnMarketableSecurities
-2658000
ortx Accretion Amortization Of Discount Premium On Marketable Securities
AccretionAmortizationOfDiscountPremiumOnMarketableSecurities
66000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1125000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
2318000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3256000
ortx Unrealized Foreign Currency And Other Non Cash Adjustments
UnrealizedForeignCurrencyAndOtherNonCashAdjustments
3177000
ortx Unrealized Foreign Currency And Other Non Cash Adjustments
UnrealizedForeignCurrencyAndOtherNonCashAdjustments
-46215000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2397000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3058000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3274000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-11315000
ortx Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
5764000
ortx Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
303000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
245000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4059000
ortx Increase Decrease In Operating Right Of Use Assets
IncreaseDecreaseInOperatingRightOfUseAssets
3356000
ortx Increase Decrease In Operating Right Of Use Assets
IncreaseDecreaseInOperatingRightOfUseAssets
7171000
ortx Increase Decrease In Accounts Payable And Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities
-8261000
ortx Increase Decrease In Accounts Payable And Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities
-178000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-286000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-4420000
ortx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-4026000
ortx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
1582000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-81233000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-63903000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
122822000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
169360000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
146671000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
71206000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
609000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6030000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24458000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
92124000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
228000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
118000
ortx Payment Of Taxes On Restricted Stock Vesting
PaymentOfTaxesOnRestrictedStockVesting
179000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
68000000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
889000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
7071000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
60089000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
118000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
647000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-3500000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-44955000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
24839000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
72639000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
60178000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27684000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
85017000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4912000
ortx Non Cash Adjustments To Operating Lease Right Of Use Assets And Liabilities
NonCashAdjustmentsToOperatingLeaseRightOfUseAssetsAndLiabilities
447000
ortx Non Cash Adjustments To Operating Lease Right Of Use Assets And Liabilities
NonCashAdjustmentsToOperatingLeaseRightOfUseAssetsAndLiabilities
530000
us-gaap Interest Paid Net
InterestPaidNet
2340000
us-gaap Interest Paid Net
InterestPaidNet
1843000
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each holder of ordinary shares is entitled to one vote per ordinary share
us-gaap Dividends Common Stock
DividendsCommonStock
0
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2023Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
56666900
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.1
CY2023Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
62333590
CY2023Q1 ortx Class Of Warrants Or Rights Sales Price Per Unit
ClassOfWarrantsOrRightsSalesPricePerUnit
6
CY2023Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
34000000
CY2023Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4250000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.1
CY2023Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
46750000
CY2023Q2 ortx Class Of Warrants Or Rights Sales Price Per Unit
ClassOfWarrantsOrRightsSalesPricePerUnit
8
CY2023Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
34000000
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
125400000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
207000
CY2023Q3 us-gaap Inventory Net
InventoryNet
6638000
CY2022Q4 us-gaap Inventory Net
InventoryNet
3400000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual for research and development expenses, the research and development tax credit receivable, share-based compensation, collaboration agreement milestones, variable consideration in revenue recognition, operating lease assets and liabilities, valuation of PIPE Warrant (as defined in Note 12) and PIPE Unit liabilities (as defined in Note 12), and income taxes. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company’s estimates.</span>
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
3000000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-47100000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2023Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
3000000
CY2022Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
3000000
CY2023Q3 us-gaap Cash Collateral For Borrowed Securities
CashCollateralForBorrowedSecurities
1300000
CY2022Q4 us-gaap Cash Collateral For Borrowed Securities
CashCollateralForBorrowedSecurities
1300000
CY2023Q3 ortx Inventory Costs Capitalized
InventoryCostsCapitalized
5400000
CY2022Q3 us-gaap Finite Lived Intangible Assets Foreign Currency Translation Gain Loss
FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
200000
us-gaap Finite Lived Intangible Assets Foreign Currency Translation Gain Loss
FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
400000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0.46
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23469000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68424000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4215000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4215000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27684000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
72639000
us-gaap New Accounting Pronouncement Or Change In Accounting Principle Description
NewAccountingPronouncementOrChangeInAccountingPrincipleDescription
ASU 2020-04
CY2023Q3 us-gaap Change In Accounting Principle Accounting Standards Update Adopted
ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
true
CY2023Q3 us-gaap Change In Accounting Principle Accounting Standards Update Adoption Date
ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
2023-01-01
CY2023Q3 us-gaap Change In Accounting Principle Accounting Standards Update Immaterial Effect
ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
true
CY2023Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
7285000
CY2023Q3 ortx Marketable Securities Fair Value Disclosure
MarketableSecuritiesFairValueDisclosure
101944000
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
109229000
CY2023Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
21068000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
27161000
CY2022Q4 ortx Marketable Securities Fair Value Disclosure
MarketableSecuritiesFairValueDisclosure
75326000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
102487000
CY2023Q3 ortx Fair Value Assets Between Levels Transfers Amount
FairValueAssetsBetweenLevelsTransfersAmount
0
CY2022Q4 ortx Fair Value Assets Between Levels Transfers Amount
FairValueAssetsBetweenLevelsTransfersAmount
0
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
102064000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
122000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
101944000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
101481000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
238000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
101248000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2023Q3 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
97086000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
98277000
CY2023Q3 ortx Available For Sale Securities Debt Maturities After One Through Three Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost
4858000
CY2022Q4 ortx Available For Sale Securities Debt Maturities After One Through Three Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost
2971000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
101944000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
101248000
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
983000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3193000
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
5655000
CY2023Q3 ortx Prepaid External Research And Development Expenses
PrepaidExternalResearchAndDevelopmentExpenses
1797000
CY2022Q4 ortx Prepaid External Research And Development Expenses
PrepaidExternalResearchAndDevelopmentExpenses
881000
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2199000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1817000
CY2023Q3 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
894000
CY2022Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
1077000
CY2023Q3 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
1659000
CY2022Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
1851000
CY2023Q3 ortx Rent Deposits Current
RentDepositsCurrent
902000
CY2022Q4 ortx Rent Deposits Current
RentDepositsCurrent
960000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7451000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6586000
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
4088000
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
767000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3321000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
4069000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
509000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3560000
CY2023Q3 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P12Y
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
86000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
347000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
347000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
347000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
347000
CY2023Q3 ortx Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
1847000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3321000
CY2023Q3 ortx Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
9915000
CY2022Q4 ortx Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
11230000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9710000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12312000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4126000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2263000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2334000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2647000
CY2023Q3 ortx Accrued Governmental Rebates
AccruedGovernmentalRebates
3910000
CY2022Q4 ortx Accrued Governmental Rebates
AccruedGovernmentalRebates
2300000
CY2022Q4 ortx Product Liability Current Portion
ProductLiabilityCurrentPortion
3685000
CY2023Q3 ortx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
29995000
CY2022Q4 ortx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
34437000
CY2019Q2 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
75000000.0
CY2021Q2 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
100000000.0
CY2023Q3 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
67000000
CY2021Q2 ortx Line Of Credit Facility Interest Payments Term
LineOfCreditFacilityInterestPaymentsTerm
P18M
CY2021Q2 ortx Line Of Credit Facility Amortization Term
LineOfCreditFacilityAmortizationTerm
P18M
us-gaap Line Of Credit Facility Frequency Of Payments
LineOfCreditFacilityFrequencyOfPayments
monthly payments
CY2021Q2 ortx Line Of Credit Facility Percentage Of Final Payment
LineOfCreditFacilityPercentageOfFinalPayment
0.035
CY2021Q2 us-gaap Line Of Credit Facility Periodic Payment Interest
LineOfCreditFacilityPeriodicPaymentInterest
1200000
CY2023Q3 ortx Long Term Debt Before Accretion Issuance Costs Net
LongTermDebtBeforeAccretionIssuanceCostsNet
24961000
CY2022Q4 ortx Long Term Debt Before Accretion Issuance Costs Net
LongTermDebtBeforeAccretionIssuanceCostsNet
31970000
CY2023Q3 ortx Long Term Debt Before Accretion Issuance Costs Net Current
LongTermDebtBeforeAccretionIssuanceCostsNetCurrent
9429000
CY2022Q4 ortx Long Term Debt Before Accretion Issuance Costs Net Current
LongTermDebtBeforeAccretionIssuanceCostsNetCurrent
9429000
CY2023Q3 ortx Long Term Debt Before Accretion Issuance Costs Net Noncurrent
LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent
15532000
CY2022Q4 ortx Long Term Debt Before Accretion Issuance Costs Net Noncurrent
LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent
22541000
CY2023Q3 ortx Accretion Related To Final Payment
AccretionRelatedToFinalPayment
630000
CY2022Q4 ortx Accretion Related To Final Payment
AccretionRelatedToFinalPayment
450000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16162000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
22991000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
2357000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
9429000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
9429000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
5084000
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
26299000
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
9429000
CY2023Q3 ortx Unamortized Portion Of Final Payment
UnamortizedPortionOfFinalPayment
525000
CY2023Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
183000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16162000
ortx Percentage Rate Of Excess Ordinary Shares
PercentageRateOfExcessOrdinaryShares
0.1999
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
16424167
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.56
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5184380
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.49
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
370430
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.16
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1068387
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.32
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
20169730
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.21
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
20169730
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.22
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
11303310
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.73
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.28
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.32
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
8100000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
2063876
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.55
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
1720200
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
649400
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
0.57
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
304836
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
2829840
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.55
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
500000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2468000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3468000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8558000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12084000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2468000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3468000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8558000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12084000
CY2022Q2 us-gaap Restructuring Reserve
RestructuringReserve
838000
CY2021Q4 us-gaap Restructuring Reserve
RestructuringReserve
6000
us-gaap Restructuring Charges
RestructuringCharges
2481000
CY2022Q3 us-gaap Restructuring Reserve Translation And Other Adjustment
RestructuringReserveTranslationAndOtherAdjustment
-206000
us-gaap Restructuring Reserve Translation And Other Adjustment
RestructuringReserveTranslationAndOtherAdjustment
-760000
CY2022Q3 us-gaap Payments For Restructuring
PaymentsForRestructuring
632000
us-gaap Payments For Restructuring
PaymentsForRestructuring
1727000
us-gaap Restructuring Charges
RestructuringCharges
0
CY2023Q3 ortx Manufacturing Commitments
ManufacturingCommitments
17746000
CY2023Q3 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
1.08
CY2022Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
6690000
us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
6846000
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
8421000
ortx Valuationallowancesandreservesforeigncurrencytranslation
Valuationallowancesandreservesforeigncurrencytranslation
-45000
CY2023Q3 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
5070000
us-gaap Valuation Allowances And Reserves Period Increase Decrease
ValuationAllowancesAndReservesPeriodIncreaseDecrease
-1160000
CY2022 us-gaap Valuation Allowances And Reserves Period Increase Decrease
ValuationAllowancesAndReservesPeriodIncreaseDecrease
-4390000
CY2023Q3 ortx Component Of Accrued Expenses And Other Current Liabilities
ComponentOfAccruedExpensesAndOtherCurrentLiabilities
3910000
CY2022Q4 ortx Component Of Accrued Expenses And Other Current Liabilities
ComponentOfAccruedExpensesAndOtherCurrentLiabilities
2300000
CY2023Q3 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
5070000
CY2022Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
6690000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1200000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1100000
CY2023Q3 ortx Manufacturing Commitments Amount Due In Remainder Of Fiscal Year
ManufacturingCommitmentsAmountDueInRemainderOfFiscalYear
1909000
CY2023Q3 ortx Manufacturing Commitments Amount Due In Next Twelve Months
ManufacturingCommitmentsAmountDueInNextTwelveMonths
10558000
CY2023Q3 ortx Manufacturing Commitments Amount Due In Year Two
ManufacturingCommitmentsAmountDueInYearTwo
5279000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
128925275
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15460598

Files In Submission

Name View Source Status
ortx-20230930_pre.xml Edgar Link unprocessable
0000950170-23-062428-index-headers.html Edgar Link pending
0000950170-23-062428-index.html Edgar Link pending
0000950170-23-062428.txt Edgar Link pending
0000950170-23-062428-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ortx-20230930.htm Edgar Link pending
ortx-20230930.xsd Edgar Link pending
ortx-ex31_1.htm Edgar Link pending
ortx-ex31_2.htm Edgar Link pending
ortx-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
ortx-20230930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ortx-20230930_cal.xml Edgar Link unprocessable
ortx-20230930_lab.xml Edgar Link unprocessable
ortx-20230930_htm.xml Edgar Link completed
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending